The combination of amivantamab plus chemotherapy for locally advanced or metastatic NSCLC with documented EGFR exon 20 insertion mutations in the setting of first-line treatment was associated with a median PFS of 11.4 months in a previous study [9]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.